In idiopathic pulmonary fibrosis (IPF), some facts or concepts based on substantial evidence,
whilst implicit for learned subspecialists, have previously been neglected and/or not …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with increasing
incidence; the median survival is only 35 months and as yet no therapy has been proven to …

Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease, with no effective
treatment and a median survival time of 2–5 yrs. The search for effective treatment has …

This perspective highlights some evidence that has hitherto been neglected, especially
because it may not have been sufficiently explicated in the clinical respiratory medicine …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor survival.
Recent studies have improved understanding of IPF and new discoveries have led to novel …

Recently updated guidelines have provided revised recommendations, based on the
GRADE criteria, for the diagnosis and pharmacological and non-pharmacological …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease. A major
breakthrough in treatment came when, after decades of clinical trials which failed to identify …

Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease.
Novel antifibrotic drugs that slow disease progression are now available. However, many …

Idiopathic pulmonary fibrosis (IPF) is a chronic and devastating disease of unknown
etiology, characterized by irreversible morphological changes, ultimately leading to lung …

During the past decade important progress has been made regarding the pathogenesis of
idiopathic pulmonary fibrosis (IPF), which is the most devastating form of idiopathic …